European commission grants marketing authorization for arikayce® liposomal 590 mg nebuliser dispersion for the treatment of ntm lung infections caused by mac in adult non-cf patients with limited treatment options

Bridgewater, n.j., oct. 28, 2020 /prnewswire/ — insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the european commission (ec) has granted marketing authorization for...
INSM Ratings Summary
INSM Quant Ranking